Published in Nature on August 05, 2007
Autophagy in the pathogenesis of disease. Cell (2008) 34.68
AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell (2008) 16.72
Regulation of cancer cell metabolism. Nat Rev Cancer (2011) 15.44
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer (2009) 8.43
Molecular basis of metastasis. N Engl J Med (2008) 8.19
Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev (2009) 6.46
AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev (2011) 5.26
LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell (2013) 4.58
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc (2009) 4.50
A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A (2008) 4.45
An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene (2009) 4.10
Metformin prevents tobacco carcinogen--induced lung tumorigenesis. Cancer Prev Res (Phila) (2010) 3.86
Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell (2009) 3.85
AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature (2012) 3.85
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell (2010) 3.40
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) (2009) 2.94
Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov (2014) 2.77
Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol (2010) 2.72
Autophagy in malignant transformation and cancer progression. EMBO J (2015) 2.67
Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer (2011) 2.64
Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov (2014) 2.55
The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression. Nat Genet (2011) 2.47
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med (2011) 2.35
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet (2015) 2.27
Somatic LKB1 mutations promote cervical cancer progression. PLoS One (2009) 2.21
Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br J Cancer (2008) 2.21
Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. Am J Physiol Lung Cell Mol Physiol (2008) 2.15
Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science (2009) 2.13
AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol (2010) 2.11
LKB1 loss links serine metabolism to DNA methylation and tumorigenesis. Nature (2016) 2.11
Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal (2009) 2.11
mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc Natl Acad Sci U S A (2009) 2.08
Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF. PLoS One (2009) 2.03
Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms. Mol Cell Biol (2008) 1.96
Evidence that SOX2 overexpression is oncogenic in the lung. PLoS One (2010) 1.93
Metabolic Heterogeneity in Human Lung Tumors. Cell (2016) 1.86
CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci (2009) 1.84
Epidemiology of cancer of the small intestine. World J Gastrointest Oncol (2011) 1.75
LKB1 and AMPK and the cancer-metabolism link - ten years after. BMC Biol (2013) 1.73
LKB1 regulates pancreatic beta cell size, polarity, and function. Cell Metab (2009) 1.70
Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol (2010) 1.69
Anoikis resistance: an essential prerequisite for tumor metastasis. Int J Cell Biol (2012) 1.67
Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics (2011) 1.67
Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis. Cancer Prev Res (Phila) (2009) 1.67
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov (2015) 1.64
Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell (2013) 1.60
AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes (2013) 1.58
Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin Cancer Res (2013) 1.56
Cell cycle-dependent ciliogenesis and cancer. Cancer Res (2008) 1.54
Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model. Clin Cancer Res (2009) 1.53
NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res (2009) 1.53
ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett (2010) 1.50
HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest (2009) 1.49
LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell (2012) 1.49
Molecular biology of lung cancer: clinical implications. Clin Chest Med (2011) 1.47
LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology (2010) 1.47
Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell (2014) 1.45
How genetically engineered mouse tumor models provide insights into human cancers. J Clin Oncol (2011) 1.43
LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis. Cancer Res (2008) 1.42
A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. Nat Cell Biol (2013) 1.41
MYC is a metastasis gene for non-small-cell lung cancer. PLoS One (2009) 1.41
LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc Natl Acad Sci U S A (2010) 1.40
A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo. Nat Methods (2017) 1.40
Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung. J Clin Invest (2012) 1.36
The pivotal role of IKKα in the development of spontaneous lung squamous cell carcinomas. Cancer Cell (2013) 1.36
SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci Signal (2009) 1.35
Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells. Oncogene (2009) 1.34
Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation increases LKB1 nucleus export and apoptosis in endothelial cells. J Biol Chem (2008) 1.31
Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. J Clin Invest (2013) 1.28
LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins. Cancer Res (2008) 1.28
Primary cilia and the cell cycle. Methods Cell Biol (2009) 1.28
Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov (2013) 1.27
Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res (2012) 1.27
Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy. Dis Model Mech (2010) 1.27
Genetic changes in squamous cell lung cancer: a review. J Thorac Oncol (2012) 1.23
Lung Cancer: Are we up to the Challenge? Curr Genomics (2010) 1.21
Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion. Oncogene (2013) 1.21
Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer. Oncogene (2011) 1.21
VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res (2014) 1.20
Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells. Cancer Res (2008) 1.20
Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent. Oncogene (2010) 1.19
NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer. PLoS One (2011) 1.19
microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions. Oncogene (2013) 1.18
Regulation of LKB1/STRAD localization and function by E-cadherin. Curr Biol (2008) 1.18
Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Res (2013) 1.16
An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. Nat Genet (2014) 1.16
Molecular pathways and therapeutic targets in lung cancer. Oncotarget (2014) 1.16
TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. Oncogene (2009) 1.16
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. Cancer Res (2014) 1.15
Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α. Proc Natl Acad Sci U S A (2014) 1.14
Role of LKB1 in lung cancer development. Br J Cancer (2008) 1.14
Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites. Am J Cancer Res (2011) 1.13
HLungDB: an integrated database of human lung cancer research. Nucleic Acids Res (2009) 1.13
Cancer genes in lung cancer: racial disparities: are there any? Genes Cancer (2012) 1.12
Pathogenesis of lung cancer signalling pathways: roadmap for therapies. Eur Respir J (2009) 1.10
HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression. Oncogene (2011) 1.10
Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas. J Thorac Oncol (2010) 1.10
Gene expression profiling of non-small cell lung cancer. Lung Cancer (2008) 1.08
The tumor suppressor kinase LKB1 activates the downstream kinases SIK2 and SIK3 to stimulate nuclear export of class IIa histone deacetylases. J Biol Chem (2013) 1.08
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet (2011) 18.88
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med (2008) 18.60
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23
Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell (2005) 15.06
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
A landscape of driver mutations in melanoma. Cell (2012) 12.61
High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat Methods (2008) 12.56
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (2005) 12.35
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell (2007) 12.33
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A (2004) 12.30
Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell (2008) 12.29
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell (2010) 11.20
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res (2010) 10.90
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol (2008) 9.43
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24
Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature (2006) 9.20
p16INK4a induces an age-dependent decline in islet regenerative potential. Nature (2006) 9.09
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell (2007) 8.94
An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86
The regulation of INK4/ARF in cancer and aging. Cell (2006) 8.75
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell (2009) 8.64
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 8.48
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Ink4a/Arf expression is a biomarker of aging. J Clin Invest (2004) 8.30
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev (2003) 8.27
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2006) 8.26
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (2004) 8.16
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A (2008) 8.08
Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature (2006) 8.06
Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol (2007) 7.97
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell (2010) 7.78
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77